Streetwise Reports' Article Archives — March 2021 back to current month (27)
Clarus Securities' initiation report on Rritual Superfoods views the company "as an attractive growth story for investors looking to gain exposure to a large and rapidly growing functional food and beverages market."
Being included in the Horizons Psychedelic Stock Index Exchange Traded Fund will afford Algernon Pharmaceuticals greater investor exposure.
Shockwave Medical Inc. shares gained 19% after the company announced that sales of its recently launched C2 Coronary IVL System are growing steadily and are driving revenue growth.
Shares of Humanigen Inc. traded 67% higher after the company reported positive topline results from its Phase 3 lenzilumab™ study indicating significant improvement in survival of hospitalized COVID-19 pneumonia patients without the need for mechanical ventilation.
ProQR Therapeutics shares reached a new 52-week high after the company reported highly positive results from its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
Catalysts expected in 2021-2022 regarding Ocugen's pipeline therapeutics are discussed in a ROTH Capital Partners report.
Knox Henderson delves into the value proposition behind Rritual Superfoods, which has just started trading this month.
Aptose Biosciences Inc. shares traded 55% higher after the company posted Q4 and FY/20 financial results and provided an update on the status of its drug candidates in ongoing clinical trials investigating treatments for life threatening hematologic cancers.
Investor Campbell Becher's Three Core Assets (03/22/2021)
The former Bay Street investment banker is finding himself going narrower and deeper.
Novamind Inc. reported it is teaming up with Merck to conduct a new Phase 2a study addressing treatment-resistant depression at a key clinical research site owned by its subsidiary company Cedar Clinical Research.
Have we forgotten about good Covid 19 Therapeutics? KSS MD PhD, editor-in-chief of PubBio.co, discusses three gems investors should know about.
Shares of Clovis Oncology Inc. traded 55% higher after it reported that in the Phase 3 ARIEL4 study Rubraca (rucaparib) significantly improved progression-free survival versus chemotherapy in patients with later-line ovarian cancer associated with a BRCA Mutation.
These corporate events and the Q4/20 financials of DURECT are summarized in an H.C. Wainwright & Co. report.
Reliq Health Technologies reported it entered into a new contract with a physician practice in Florida to provide its iUGO Care platform to over 25 skilled nursing facilities statewide.
Algernon Pharmaceuticals reported that it expects to release topline results from the Phase 2b portion of its multinational Phase 2b/3 COVID-19 Ifenprodil study sometime during the last week of March 2021.
Oncternal Therapeutics shares traded 18% higher after the company reported Q4/20 and FY/20 financial results showing higher revenues from grants and improved operating expense without incurring any reductions in Research and Development activities.
Vir Biotechnology shares traded 30% higher after the company together with its development partner GlaxoSmithKline reported that in the Phase 3 COMET-ICE trial VIR-7831 was shown to reduce hospitalization and risk of death in early treatment of adults with SARS-CoV-2.
Biopharma Begins Phase 2 COVID Clinical Trial (03/10/2021)
An update on two of Can-Fite BioPharma's studies involving its lead drug candidate Piclidenoson is provided in a Dawson James report.
Shares of 3D printing firm Materialise NV traded higher after the company reported FY/20 financial results and indicated that sequential quarterly revenue rebounded, increasing by 11.1% in Q4/20.
Shares of RadNet Inc. reached a new 52-week high after the diagnostic imaging company reported record revenue and adjusted EBITDA for Q4/21 and offered positive financial guidance for FY/21.
The positive results of two studies of Avivagen's OxC-beta in broiler poultry are slated for publication in Poultry Science.
Second Sight Medical Products shares trade more than 400% higher after the company reported that the FDA granted approval for its Argus 2s Retinal Prosthesis System designed to deliver useful artificial vision to blind individuals diagnosed with retinitis pigmentosa.
Five Prime Therapeutics shares traded 78% higher after the company reported it entered into a definitive agreement to be acquired by biotech giant Amgen for $38 per share in cash.
This latest undertaking of Dicerna Pharmaceuticals and the near-term catalysts of some of its other programs are described in an H.C. Wainwright & Co. report.
Reliq Health Technologies reported financial results for Q2/21 that demonstrated significant increases in quarterly revenues and gross margins; management expects to achieve profitability in the quarter ending June 30, 2021.
Asensus Surgical shares traded 16.5% higher after the company reported it received clearance from the U.S. Food & Drug Administration for its Senhance© Surgical System for use in general surgical procedures.
Algernon Pharmaceuticals aims to begin the study as soon as it receives the drug from the manufacturer.
|"Momentum continues to build for VIV."|